Familial prostate cancer
Gene: BRCA1Spoke to Clare Turnbull about this gene; ok to leave amber at this stage as it is not a clear-cut gene for familial prostate cancer. Only BRCA2 is included on the pertinent germline gene list for the cancer programme.Created: 7 Mar 2017, 1:13 p.m.
Added the 'stratified medicine' tag to indicate the use of PARP inhibitors may be a new therapeutic option for prostate cancer patients with BRCA variants.Created: 26 Jan 2017, 3:41 p.m.
Comment on list classification: Seems to be some controversy over the risk of BRCA1 germline variants and prostate cancer, however a large UK study found a significant increased risk; PMID:22516946.Created: 26 Jan 2017, 3:31 p.m.
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Tag stratified-medicine was removed from gene: BRCA1.
Phenotypes for gene: BRCA1 were changed from to Prostate cancer, MONDO:0008315
07/03/2017 - revised and ready to promote to version 1.
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001); 27188668; 26926928; 26360800 - no increased risk; 26236408 - literature review indicating there is conflicting reports; 22516946; 28031937
This gene has been classified as Amber List (Moderate Evidence).
This gene has been classified as Amber List (Moderate Evidence).
Mode of inheritance for BRCA1 was changed to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001); 27188668; 26926928; 26360800 - no increased risk; 26236408 - literature review indicating there is conflicting reports;22516946
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001); 27188668; 26926928; 26360800 - no increased risk;26236408 - literature review indicating there is conflicting reports
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001); 27188668; 26926928;26360800 - no increased risk
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001); 27188668;26926928
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001);27188668
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846; 27317574; 27306910 - standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001).
Publications for BRCA1 were set to 27989354; 27899188; 27742670; 27433846;27317574
Publications for BRCA1 were set to 27989354;27899188;27742670;27433846
BRCA1 was added to Familial prostate cancerpanel. Sources: Expert list
BRCA1 was created by ellenmcdonagh